ArticleAmerican journal of translational research2026
Perioperative antiplatelet management in CAD patients undergoing spinal fusion: balancing cardiovascular safety and bleeding risk.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor patients with coronary artery disease (CAD) who require long-term antiplatelet therapy, controversy remains regarding perioperative drug management strategies during spinal fusion surgery, with balancing thrombotic and bleeding risks being key to clinical decision-making.
objectiveThis study aims to retrospectively compare the impact of four perioperative antiplatelet drug management strategies (continuing medication, discontinuing medication 5 days before surgery, discontinuing medication 7 days before surgery, and bridging therapy) on cardiovascular safety and bleeding risk in CAD patients undergoing spinal fusion surgery.
methodsThis is a single-center retrospective cohort study. It includes 325 patients with CAD who underwent elective spinal fusion surgery between January 2018 and December 2023. Patients were divided into four groups based on their perioperative antiplatelet management strategy. The primary outcome was major adverse cardiovascular events (MACE) within 30 days post-surgery, while secondary outcomes included bleeding events, intraoperative blood loss, postoperative drainage volume, and transfusion requirements.
resultsBaseline characteristics were generally balanced across the four groups. The group continuing medication had the highest incidence of bleeding events (31.9%), whereas the group discontinuing medication 7 days preoperatively had the lowest (6.7%), with significant differences observed (P<0.001). Regarding cardiovascular events, the incidence was relatively lower in the group continuing medication, with higher risk in the discontinuation groups (especially the 5-day discontinuation group); multivariate regression showed that discontinuing medication for 5 days was an independent risk factor for MACE (OR=3.87, P=0.038). The bridging therapy group exhibited intermediate levels of both bleeding and cardiovascular risk. Intraoperative blood loss and postoperative transfusion rates were also significantly higher in the continuing medication group.
conclusionsIn spinal fusion surgeries among CAD patients, continuing antiplatelet medication provides better cardiovascular protection but significantly increases bleeding risk; discontinuing medication preoperatively can effectively reduce bleeding complications but may increase the risk of cardiovascular events; while bridging therapy achieves a relative balance between the two. Clinical decisions should be individualized, comprehensively assessing the patient's thrombotic and bleeding risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.